A message to patients who have received the Johnson & Johnson/Janssen COVID-19 vaccine
Out of an abundance of caution, the Indian Health Service has paused the use of the Johnson & Johnson/Janssen COVID-19 vaccine as the Food and Drug Administration and the Centers for Disease Control and Prevention reviews data involving six reported U.S. cases of an extremely rare and severe type of blood clot in individuals after receiving the Johnson & Johnson/Janssen vaccine.
Seek medical care urgently if you develop any of the following symptoms:
- severe headache,
- new neurologic symptoms,
- severe abdominal pain,
- shortness of breath,
- leg swelling,
- tiny red spots on the skin (petechiae), or
- new or easy bruising
To date, there have been no cases reported through IHS of the rare and severe type of blood clot seen in some individuals who have received the Johnson & Johnson/Janssen vaccine.
If you had an appointment scheduled to receive the Johnson & Johnson/Janssen COVID-19 vaccine talk to your health care provider about whether the Pfizer or Moderna vaccine is available and appropriate for you.
The Indian Health Service continues to work closely with our tribal partners and state and local public health officials to coordinate a comprehensive public health response to the ongoing COVID-19 pandemic. The federal government is working closely with state, local, tribal, and territorial partners, as well as public health partners, to respond to this public health threat.
The IHS has received nearly $3 billion in funding to provide resources for IHS, tribal, and urban Indian health programs to prepare for and respond to the coronavirus pandemic. We have worked closely with tribes and urban Indian organizations throughout this pandemic to get resources out to facilities as quickly as possible.
The IHS is committed to COVID-19 vaccine availability for all individuals within our health system. The IHS is working diligently with our CDC partners to report and validate vaccine administration data. Information on the number of COVID-19 vaccines administered across the IHS can be found on the CDC COVID Data Tracker in the Federal Entities section.
More information on the IHS response can be found in the IHS Covid-19 Response 100 Day Review [PDF – 411 KB] and Executive Summary [PDF – 207 KB]. This report covers actions taken by the IHS to support federal, tribal, and Urban Indian Organizations between March 6, 2020 through June 14, 2020.
For the latest general information about COVID-19, we encourage everyone to periodically review CDC’s COVID-19 webpage .
COVID-19 Vaccine Distribution and Administration by IHS Area
As of April 12, 2021, the IHS is distributing vaccine allocations of the Pfizer, Moderna, and Johnson & Johnson/Janssen vaccine. The table below shows the total number of vaccine doses distributed and administered per IHS Area to date.
|Area||Total Doses Distributed*||Total Doses Administered**|
*Distributed Data Source: IHS National Supply Service Center, includes total doses ordered and anticipated to be delivered by April 5, 2021, delays such as weather may impact full delivery by the end of the week.
**Administered Data Source: CDC Clearinghouse data from Vaccine Administration Management System (VAMS) and IHS Central Aggregator Service (CAS). Data in the CDC Clearinghouse reflects prior day data. Data may be different than actual data as there are known CDC data lags and ongoing quality review of data including resolving data errors.
^The Tucson Area vaccine administration data is currently being validated.
Note: Alaska Area – all tribes chose to receive COVID-19 vaccine from the State of Alaska.
COVID-19 Cases by IHS Area
Data are reported from IHS, tribal, and urban Indian organization facilities, though reporting by tribal and urban programs is voluntary. Data reflect cases reported to the IHS through 11:59 pm on April 16, 2021.
* Cumulative percent positive and 7-day rolling average positivity are updated three days per week.
Website last updated April 17, 2021